Please provide your email address to receive an email when new articles are posted on . Approximately 40,000 people in the United States have skin sarcoidosis and there is no FDA-approved treatment.
Sirolimus may be an effective treatment for patients with persistent cutaneous sarcoidosis. In a small clinical trial, 7 of 10 patients treated with sirolimus via oral solution had improvements in ...
NEW YORK CITY -- Patients with longstanding sarcoidosis and skin involvement had dramatic improvement after 6 months of treatment with the Janus kinase (JAK) inhibitor tofacitinib (Xeljanz), a small ...
Sarcoidosis is a rare systemic disease that afflicts an estimated 200,000 people in the US, more often people who are Black and more women than men, particularly when it causes chronic skin disease.
February 20, 2026 (Washington, DC)—The Milken Institute Science Philanthropy Accelerator for Research and Collaboration (SPARC), in partnership with the Ann Theodore Foundation (ATF), has launched a ...
In a study of patients with cutaneous sarcoidosis, ECG abnormalities identified all cases of cardiac involvement, demonstrating 100% sensitivity and 100% negative predictive value. Researchers ...
Brepocitinib 45 mg significantly improved cutaneous sarcoidosis disease activity, achieving a 22.3-point improvement in mean CSAMI-A at Week 16 versus a 0.7-point improvement in placebo (Δ21.6 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results